Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.44 |
| ▸ | HCN1 | O60741 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2887526 | 0.92 | KCNH2 (0.63) | KCNH2CACNA1ISLC6A9HCN1GAA | |
| SCHEMBL2884515 | 0.83 | KCNH2 (0.66) | KCNH2CACNA1IGPR139CHRM3POLB | |
| SCHEMBL2887076 | 0.83 | KCNH2 (0.69) | KCNH2CACNA1ISLC6A9CHRM3DRD4 | |
| SCHEMBL2887579 | 0.82 | KCNH2 (0.67) | KCNH2MAPTCACNA1IGAASMN1; SMN2 | |
| SCHEMBL2882537 | 0.82 | KCNH2 (0.80) | KCNH2CACNA1IPOLBDRD4DRD2 | |
| SCHEMBL2887877 | 0.81 | KCNH2 (0.66) | KCNH2MAPTCACNA1INPC1RAB9A | |
| SCHEMBL2888243 | 0.80 | KCNH2 (0.73) | KCNH2MAPTCACNA1IGAANPC1 | |
| SCHEMBL8247737 | 0.77 | CACNA1I (0.62) | KCNH2MAPTCACNA1INPC1RAB9A | |
| SCHEMBL3516190 | 0.77 | CACNA1I (0.62) | KCNH2MAPTCACNA1INPC1RAB9A | |
| SCHEMBL2887437 | 0.77 | KCNH2 (0.69) | KCNH2MAPTCACNA1INPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501773-B2 | 4-fluoro-piperidine T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | claimed |
| EP-1901746-B1 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-02-20 | — | — | EP | claimed |
| US-20100216841-A1 | 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | claimed |
| EP-1901746-A2 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck & Co., Inc. (US) | 2008-03-26 | — | — | EP | claimed |
| WO-2007002884-A2 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-8501773-B2 | 4-fluoro-piperidine T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501773-B2 | 4-fluoro-piperidine T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501773-B2 | 4-fluoro-piperidine T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-1901746-B1 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-02-20 | — | — | EP | disclosed |
| EP-1901746-B1 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20100216841-A1 | 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216841-A1 | 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216841-A1 | 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| WO-2007002884-A2 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216841-A1 | 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists | CACNA1G, CACNA1I, CACNA1H | KCNH2 38/4885MAPT 243/4885CACNA1I 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.